α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptor activation protects against phencyclidine-induced caspase-3 activity by activating voltage-gated calcium channels.
Jennifer M Timpe, Cheng Z Wang, Jisoo Kim, Kenneth M Johnson
Journal of Neuroscience Research December 2014 DOI: 10.1002/jnr.23446 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Basic science laboratory study Peer reviewed |
|---|---|
| Population | Organotypic neonatal rat brain slices |
| Interventions | AMPA PCP cadmium chloride nifedipine ω-agatoxin TK ω-conotoxin K252a |
| Dose | nifedipine 10 µM; ω-agatoxin TK 200 nM; ω-conotoxin 2 µM |
| Keywords | Ampa Nmda Calcium Neurotoxicity Phencyclidine |
| Key points | AMPA protects against PCP-induced apoptosis in neonatal rat brain slices, and this protection requires L-type voltage-dependent calcium channels, with a smaller contribution from P/Q-type channels and a role for TrkB/BDNF signaling. The authors suggest that activating these calcium channels might benefit conditions involving diminished NMDAergic activity during early development. |
Abstract
Phencyclidine (PCP) is a noncompetitive, open channel blocker of the N-methyl-D-aspartate (NMDA) receptor-ion channel complex. When administered to immature animals, it is known to cause apoptotic neurodegeneration in several regions, and this is followed by olanzapine-sensitive, schizophrenia-like behaviors in late adolescence and adulthood. Clarification of its mechanism of action could yield data that would help to inform the treatment of schizophrenia. In our initial experiments, we found that α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) inhibited PCP-induced apoptosis in organotypic neonatal rat brain slices in a concentration-dependent and 6-cyano-7-nitroquinoxaline-2,3-dione-sensitive manner. Calcium signaling pathways are widely implicated in apoptosis, and PCP prevents calcium influx through NMDA receptor channels. We therefore hypothesized that AMPA could protect against this effect by activation of voltage-dependent calcium channels (VDCCs). In support of this hypothesis, pretreatment with the calcium channel blocker cadmium chloride eliminated AMPA-mediated protection against PCP. Furthermore, the L-type VDCC inhibitor nifedipine (10 µM) fully abrogated the effects of AMPA, suggesting that L-type VDCCs are required for AMPA-mediated protection against PCP-induced neurotoxicity. Whereas the P/Q-type inhibitor ω-agatoxin TK (200 nM) reduced AMPA protection by 51.7%, the N-type VDCC inhibitor ω-conotoxin (2 µM) had no effect. Decreased AMPA-mediated protection following cotreatment with K252a, a TrkB inhibitor, suggests that brain-derived neurotrophic factor signaling plays an important role. By analogy, these results suggest that activation of L-type, and to a lesser extent P/Q-type, VDCCs might be advantageous in treating conditions associated with diminished NMDAergic activity during early development.
Citations in the library
Cites 7
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Brain-derived neurotrophic factor prevents phencyclidine-induced apoptosis in developing brain by parallel activation of both the ERK and PI-3K/Akt pathways. Neuropharmacology February 2010
- Activation of dopamine D1 receptors blocks phencyclidine-induced neurotoxicity by enhancing N-methyl-D-aspartate receptor-mediated synaptic strength. Journal of Neurochemistry May 2009
- Lithium protection of phencyclidine-induced neurotoxicity in developing brain: the role of phosphatidylinositol-3 kinase/Akt and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling pathways. Journal of Pharmacology and Experimental Therapeutics September 2008
- The role of Akt-GSK-3beta signaling and synaptic strength in phencyclidine-induced neurodegeneration. Neuropsychopharmacology May 2008
and 2 more in the library